BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The process of identifying and prioritizing promising lead drug candidates in antibody drug discovery is often inefficient due to the complexity of multi-omics data analysis and the challenges in predicting drug interactions and efficacy. Traditional methods struggle to rapidly provide comprehensive insights needed for informed decision-making.
Solution
BioStrand offers the LENSai™ Integrated Intelligence Technology, a cloud-hosted SaaS platform designed to accelerate antibody drug discovery through advanced computational methods. This technology analyzes multi-omics data, integrating vast datasets from diverse sources to provide a unified view and rapid insights. By employing proprietary algorithms and HYFTs, a novel computational language, LENSai facilitates the efficient evaluation of drug interactions and prioritizes candidates based on predicted efficacy, toxicity, and functional properties. The platform enables researchers to identify lead drug candidates for potential therapeutic interventions, improving the selection process and overall efficiency of drug discovery.
Target Audience
The primary users are biotech companies and researchers involved in antibody drug discovery, biotherapeutics, and precision medicine who need advanced tools for multi-omics data analysis and lead candidate identification.
Features
- Cloud-based SaaS platform for biotherapeutic data management and analysis
- LENSai™ Integrated Intelligence Technology for multi-omics data analysis
- HYFTs computational language for detailed and scalable insights
- Rapid identification of lead drug candidates
- Prediction of drug interactions, efficacy, and toxicity
- Prioritization of candidates based on functional properties
- Unified and integrated data view for rapid insights and collaboration